Accretion Pharmaceuticals Ltd
Accretion Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
4 of 4 strong
The short version
The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
From Accretion Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue.
- Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets.
- They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth.
- FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum.
- The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels.
2 more points from Accretion Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Accretion Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
- The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance.
- Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities.
- Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth.
- Working capital has been augmented to support growing orders and ensure operational agility.
2 more points from Accretion Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Accretion Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters.
- They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity.
- New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book.
2 more points from Accretion Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Accretion Pha.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Accretion Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Accretion Pharmaceuticals Ltd Q2 FY26 results?
The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
What is Accretion Pharmaceuticals Ltd share price analysis?
Accretion Pharmaceuticals Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 20.8 with a market cap of ₹201 Cr. Investors should review the full earnings analysis for detailed insights.
Is Accretion Pharmaceuticals Ltd planning capital expenditure?
The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
Keep Accretion Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.